POPA Recon📢 AbbVie Nears Record Highs: Have Its Post-Humira Growth Engines Taken Over? 👀
📢 AbbVie Nears Record Highs: Have Its Post-Humira Growth Engines Taken Over? 👀 ✍️ Core Thesis :- AbbVie is successfully executing a product cycle transition—a rare feat among major pharmaceutical companies. While Humira remains in rapid decline, Skyrizi and Rinvoq have generated sufficient revenue scale to steer the company back onto a growth trajectory. 🔴Humira Is Still Declining, but the Transition Has Already Happened 🔴Neuroscience and Oncology Are Adding a Second Layer of Growth 🔴AbbVie Is Still Building for the Next Decade 🔗 Read More :- https://www.bitget.com/news/detail/125606058389…
The excerpt is quoted from a public Telegram channel, which owns its text.